Home・Akcijų sąrašas・TG Therapeutics Inc

TG Therapeutics Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

45.96 -11.27

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

45.75

Max

51.8

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-3.3M 20M
Pardavimai	12M 205M
P/E Sektoriaus vid.	19.493 64.641
Pelnas, tenkantis vienai akcijai	0.18
Pelno marža	9.651
Darbuotojai	399
EBITDA	-24M 28M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+22.74% upside

Dividendai
By Acuity
Kitas uždarbis	2026-08-03

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	3.1B 8.5B
Ankstesnė atidarymo kaina	57.23
Ankstesnė uždarymo kaina	45.96

Naujienos nuotaikos

By Acuity

17%

83%

24 / 340 reitingas Healthcare

TG Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-07-31 23:16; UTC

No specific news was identified for TG Therapeutics Inc. After-market trading remains routine, with the stock showing little change in value.

2026-07-30 23:56; UTC

TG Therapeutics Inc shares are lower in after-market hours, with no specific news identified for the decline amid broader market uncertainty over interest rates.

2026-07-29 15:52; UTC

Social Media

News

TG Therapeutics shares are lower amid negative sentiment following the announcement of a conference call to discuss second quarter results and future outlook.

2026-07-28 19:56; UTC

TG Therapeutics shares are lower today amid broader market declines and a significant drop in the Nikkei 225 Index, reflecting negative sentiment.

2026-07-27 19:07; UTC

Social Media

B. Riley raised its price target for TG Therapeutics to $86, citing strong demand for Briumvi and anticipated revenue growth. Shares are trading roughly flat.

2026-07-24 23:21; UTC

TG Therapeutics Inc shares are lower in after-market hours, reaching a significant decline and hitting the lowest point of the day. No specific news was identified.

2026-07-23 23:22; UTC

TG Therapeutics traded roughly flat in after-market hours, with minimal change since Thursday's close, oscillating within its one-month trading range.

2026-07-22 23:31; UTC

TG Therapeutics Inc shares declined in after-market trading, reflecting a shift toward the lower end of its one-month trading range amid broader market pressures.

2026-07-21 22:21; UTC

TG Therapeutics shares are higher in after-market trading, tracking broader market gains following positive earnings from General Motors and 3M.

2026-07-20 23:22; UTC

TG Therapeutics shares are higher in after-market trading, recovering from a prior dip despite broader market pressures and four consecutive sessions of declines.

Akcijų palyginimas

Kainos pokytis

TG Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

22.74% į viršų

12 mėnesių prognozė

Vidutinis 63.86 USD 22.74%

Aukščiausias 86 USD

Žemiausias 20 USD

Remiantis 7 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines TG Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

7 ratings

Pirkti

Laikyti

Parduoti

Remiantis 7 analitikų, pateikusių TG Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

24 / 340 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę TG Therapeutics Inc

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.